Linnaeus wins $22m to address aging before decline
ARPA-H awarded up to $22 million to Linnaeus Therapeutics to test LNS8801 for preserving intrinsic capacity and healthspan. The drug, originally developed in oncology and given to over 100 cancer patients, will progress from preclinical aging studies to a randomized trial in healthy older adults measuring function and biological aging markers.
Why it mattersARPA-H's $22M award launches an LNS8801 randomized trial in healthy older adults, guiding investment and development decisions.
Entities Mentioned
ARPA-H